AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01468025
Drug: Active Theramine and Active Naproxen
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
Trial: NCT01468025
Drug: Naproxen and Theramine-like placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naproxen co-administered with Theramine-like placebo.
Trial: NCT02498418
Drug: Xifaxan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, brand product.
Trial: NCT02498418
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets in the same image of the generic rifaximin. Has no active ingredient.
Trial: NCT02038803
Drug: TOBIpodhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03386357
Drug: B (pembrolizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200mg absolute, q3w)
Trial: NCT03970304
Drug: Vivotif Typhoid Oral Vaccine
RxNorm normalized name: Vivotif Typhoid Oral Vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 4 doses (1 capsule each) will be administered on alternate days, e.g., days 0, 2, 4, and 7 (± 1 day) under the supervision of the study coordinator(s).
Trial: NCT01492101
Drug: NKTR-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 145 mg/m2 NKTR-102 will be delivered q21day as a 90-minute intravenous (IV) infusion on day 1 of each treatment cycle.
Trial: NCT00577005
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01004432
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will continue taking their current Methotrexate (MTX) treatment regimen.
Trial: NCT01046357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01652625
Drug: Placebo toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
Trial: NCT00629161
Drug: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
Trial: NCT00629161
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months period of placebo plus 1 month period without placebo
Trial: NCT00577096
Drug: Total Therapy II
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
Trial: NCT00577096
Drug: Heparin, Low-Molecular-Weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who received thalidomide also received prophylactic low molecular weight heparin
Trial: NCT02411318
Drug: ProLab 200mg caffeine capsule
RxNorm normalized name: caffeine 200 MG
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will swallow one ProLab caffeine 200mg tablet.
Trial: NCT02411318
Drug: Glucose Tolerance Drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will consume 100 grams of glucose
Trial: NCT00034918
Drug: ZD6474
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02696434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dosing
Trial: NCT00832650
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OD for 14 days
Trial: NCT00658177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT00336375
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment doses given either accompanied or not-accompanied with intake of fatty food.
Trial: NCT02961816
Drug: Caphosol
RxNorm normalized name: Caphosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caphosol oral rinses 30 mL four times a day used from Day -8.
Trial: NCT02961816
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg by vein or mouth three times a day from Day -1.
Trial: NCT06584773
Drug: standard maintenance immunosuppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard maintenance immunosuppression: tacrolimus, mycophenolate, prednisone
Trial: NCT01792206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
Trial: NCT05080361
Drug: BRAF inhibitor
RxNorm normalized name: B-Raf serine-threonine kinase (BRAF) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reports of adverse events occurring in patients treated with at least one BRAFi or MEKi as reported in the individual case safety reports.
Trial: NCT00445744
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00445744
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01245816
Drug: Eflornithine plus Sulindac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
Trial: NCT01245816
Drug: Eflornithine plus Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
Trial: NCT01245816
Drug: Sulindac plus Placebo
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
Trial: NCT01230216
Drug: control systolic blood pressure less than 120 mmHg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use losartan to control blood pressure
Trial: NCT01230216
Drug: control systolic blood pressure less than 140 mmHg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use losartan to control blood pressure
Trial: NCT00427999
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00672399
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
Trial: NCT01510535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First 2 weeks Placebo(2ml) once weekly in experimental group
Trial: NCT01510535
Drug: Hyruan Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
Trial: NCT01510535
Drug: LBSA0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: at third week LBSA0103(60mg) once in experimental group
Trial: NCT01562821
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An initial placebo bolus dose followed by placebo every second hour until completion of surgery
Trial: NCT02736591
Drug: Growth Hormone-Releasing Hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
Trial: NCT02736591
Drug: Placebo 1
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
Trial: NCT02736591
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
Trial: NCT01370564
Drug: Diuretics
RxNorm normalized name: DIURETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
Trial: NCT03000530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02014922
Drug: TheraTears® Lubricant Eye Drop
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02014922
Drug: TheraTears® preservative-free single-use containers
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00104468
Drug: Troxatyl™ (Cytotoxic Chemotherapeutic)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01982461
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg,once daily
Trial: NCT01982461
Drug: Crestor®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg,once daily
Trial: NCT01618916
Drug: LY3015014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00865241
Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
Trial: NCT00655512
Drug: hydrocortisonacetat 1% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Trial: NCT00655512
Drug: betamethasonvalerat 0,1% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
Trial: NCT00655512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
Trial: NCT01507402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (inactive substance)
Trial: NCT02963922
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injected subcutaneously (s.c., under the skin) once daily
Trial: NCT03554200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care + Placebo: Matching Placebo (tablets) once daily
Trial: NCT02784535
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01839799
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
Trial: NCT03735368
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo oral capsules
Trial: NCT03735368
Drug: topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical anesthesia of the eye by Benoxinate Hydrochloride 0.4% Eye Drops
Trial: NCT00580047
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg IV Annually
Trial: NCT02020551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01836809
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
Trial: NCT01478256
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical erythromycin ointment twice a day
Trial: NCT04671251
Drug: AEVI-007
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg of AEVI-007 and will be reconstituted with 1.2 mL of water for injection.
Trial: NCT02275351
Drug: SM04554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution, applied once a day
Trial: NCT04150250
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy may include:~* Ciprofloxacin 500 mg, twice daily;~* Azithromycin 500 mg, once daily (for those persons who are allergic to fluoroquinolones);~* Doxycycline 300 mg, once daily (for those persons who are allergic to fluoroquinolones)
Trial: NCT01339156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part A:~The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.~Part B:~Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).~The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.~Part D:~Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery).
Trial: NCT01825785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT03317457
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anthracycline
Trial: NCT01285492
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
Trial: NCT03362853
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receive a single dose in a fasting state
Trial: NCT01918852
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003541
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00475878
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule/day for 3 months
Trial: NCT00096993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided as a single-use formulation for infusion.
Trial: NCT02865811
Drug: Pegylated Liposomal Doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see Arms for description.
Trial: NCT03787680
Drug: AZD6738
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 mg by mouth daily for days 1-7 of a 28-day cycle.
Trial: NCT00003541
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003541
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01529853
Drug: SAR156597
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT01529853
Drug: Placebo (for SAR156597)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT01411176
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is included same additives as active comparator.
Trial: NCT03761225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02074319
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment as usual or standard treatment for psychosis will be common in all arms
Trial: NCT02173249
Drug: AC 170 0.24%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 drop in each eye 2 times daily for 1 week
Trial: NCT01882088
Drug: Mucofalk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
Trial: NCT00128908
Drug: Rapidly Cycled HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00507832
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: twice daily topical
Trial: NCT00938587
Drug: PF-04171327 10 mg
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PF-04171327 10 mg tablet every day for 14 days
Trial: NCT03274752
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
Trial: NCT03003000
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03003000
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03003000
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03326752
Drug: DV281 (RP2D)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Dose Expansion will be enrolled into 4 groups based on NSCLC characteristics.
Trial: NCT02089087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04129775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intratympanic injection of placebo
Trial: NCT02592434
Drug: CP-690,550 (tofacitinib)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.~During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.~Body Weight (Dosage in tablet \[BID\] or solution \[BID\]):~5\<7kg (2mg or 2mL); 7\<10kg(2.5mg or 2. mL); 10 \<15kg (3mg or 3mL); 15\<25kg (3.5mg or 3.5mL); 25\<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).~Oral solution (1 mg/mL) is used for subjects \<40 kg. Oral tablets (5 mg) are used for subjects \>=40 kg.
Trial: NCT02630927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be tested.
Trial: NCT03085771
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
Trial: NCT01358175
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01044758
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule twice daily (2 weeks)
Trial: NCT00469495
Drug: Anti-helminthic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00465699
Drug: Topical B12 0.07%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00871013
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by vein days 5-8 continuous infusion
Trial: NCT03904693
Drug: Placebo FDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
Trial: NCT04026022
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plaster in the ER or PACU
Trial: NCT02586961
Drug: 0.9% saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo:~Nebulized 0.9% saline solution
Trial: NCT00367445
Drug: Inhaled Human Insulin (Exubera)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00475436
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00072826
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03022734
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
Trial: NCT01397240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Tab, twice a day, 12 weeks
Trial: NCT01438931
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no